Introduction
Over time, the prevalence of prediabetes (fasting blood glucose 5.5-6.9 mmol/l) and diabetes has increased in the United States (US). [1] [2] [3] People with diabetes have a higher risk of heart disease and stroke than people without diabetes, 4 and those with prediabetes have a higher risk of these diseases than those without the precondition. [4] [5] [6] [7] Thus, intervention programmes are needed to prevent both pre-diabetes and diabetes and to control heart disease risk factors among people with these conditions.
The Well-Integrated Screening and Evaluation for Women Across the Nation (WISEWOMAN) 8, 9 project is a US Centers for Disease Control and Prevention (CDC) funded, multicomponent intervention programme aimed at reducing heart disease and stroke risk in low-income, underinsured, and uninsured women aged 40-64 years. WISEWOMAN provides preventive services including blood pressure (BP), cholesterol, and glucose screening; lifestyle interventions to help women develop a healthier diet, increase physical activity, and quit smoking; referrals for medical treatment for participants with abnormal values; and one-year follow-up visits to provide feedback to participants and their providers about changes in participants' risk factor profiles. 9 The goal of the programme is to improve participants' health by reducing risk, by offering heart disease and strokeprevention activities in conjunction with the National Breast and Cervical Cancer Early Detection Program (NBCCEDP).
Patient-centered lifestyle programmes are especially important for low-income women because they typically receive inconsistent care. For example, roughly one in five (18%) working-age women in the US lacks health insurance, 10 and ethnic minority women -even when insured -are less likely than white women to have a consistent relationship with a healthcare provider. 11 Ensuring access to preventive health serv-ices requires expanding healthcare coverage, and fostering consistent and trusting relationships between providers and patients. 12 Thus, preventive healthcare strategies that are sensitive to the economic and cultural context of women's lives are needed.
With funding from Congress in 1995, CDC invited state and territorial departments of health and tribal agencies to design creative strategies that would add cardiovascular disease (CVD) screening and lifestyle interventions to breast and cervical cancer screening programmes. Fifteen state and tribal health agencies now operate WISEWOMAN projects (Figure 1 ).
Using social cognitive theory and the socio-ecological model, WISEWOMAN interventions are tailored to each woman and are designed to improve participants' selfefficacy, self-monitoring, readiness to change, social support, collaborative goal-setting and ability to overcome barriers, by taking small achievable steps. Many projects also use motivational interviewing. 8, 9 Baseline fasting glucose levels appear to be increasing in WISE-WOMAN participants (Figure 2 ), especially in comparison with the levels in the general US population (National Health and Nutrition Examination Study, 1999 Study, -2004 . 13 Therefore, understanding whether participation in the WISEWOMAN programme improves health outcomes is important for planning diabetes prevention efforts. The goal of this paper is to quantify the baseline prevalence of pre-diabetes and diabetes in WISE-WOMAN participants, and assess one-year changes in glucose levels and other heart disease and stroke risk factors.
Methods

WISEWOMAN projects
We restricted our analysis to the 10 WISEWOMAN projects that offer diabetes and pre-diabetes screenings and, at the time of the analysis, had both baseline and one-year follow-up data on participants.
Data Collection
Programme participants were screened at baseline and again 10-14 months later to assess changes in risk factors. For measurements of BP and cholesterol, WISEWOMAN projects follow guidelines from the Joint National Committee 14 and the Adult Treatment Panel 15 for detection, evaluation and treatment of high BP and cholesterol levels, respectively. For example, all projects measured BP twice during each visit.
At baseline and one-year followup, all projects measured height, weight, systolic and diastolic BP, total and high-density lipoprotein (HDL) cholesterol levels, and blood glucose levels. Participants were also asked whether they had ever been diagnosed as having diabetes, high cholesterol, or hypertension and if so, whether they were taking medication to treat these conditions. Participants also indicated whether they smoked cigarettes. The programmes collected demographic data on age, race, Hispanic or Latino origin, and education. The WISEWOMAN data collection protocol has been approved by the RTI International institutional review board.
Definitions
Based on American Diabetes Association guidelines, participants were considered to have pre-diabetes if they had fasting blood glucose levels of 5.5-6.9 mmol/l. They were considered to have diabetes if they had fasting blood glucose levels of ≥7 mmol/l or a self-reported history of diabetes, or if they were taking medication for diabetes. 5 Participants who were newly diagnosed with diabetes were those with abnormal glucose values at baseline (i.e. fasting blood glucose levels ≥7 mmol/l) who reported that they had never been told by a healthcare professional that they had diabetes. Participants with previously diagnosed diabetes were defined as those who reported having been told by a healthcare professional that they had diabetes. 4 
Measures
We assessed baseline prevalence of pre-diabetes and diabetes and the percentage of newly diagnosed cases of diabetes among 29 387 WISEWOMAN participants screened at baseline between January 1998 (North Carolina is the only project for which screening data are available from 1998. Other projects began screening from 2000 onwards) and June 2005. A total of 23% of programme participants screened at baseline were re-screened one year later. We assessed one-year changes in CHD risk factors (systolic and diastolic BP, total cholesterol, fasting blood glucose, body mass index [BMI], smoking prevalence, and 10-year risk of CHD) in 688 WISEWOMAN participants with baseline pre-diabetes, 83 participants with newly diagnosed diabetes at baseline, and 260 participants with previously diagnosed diabetes.
We calculated the 10-year risk of developing CHD (including angina pectoris, recognised and unrecognised myocardial infarction, coronary insufficiency [unstable angina], and CHD death) with an algorithm developed by Anderson et al 16 that uses age, systolic BP, total and HDL cholesterol, diabetes and smoking status as input risk factors. Our rationale for selecting this algorithm was based on our previous work demonstrating the Anderson algorithm to be the most appropriate calculator for tracking changes in CHD risk among WISE-WOMAN participants. 17 Age and diabetes status remained unchanged from baseline to follow-up when calculating changes in CHD risk. 17 
Analysis
We estimated one-year changes in risk factors using ordinary least squares regression analysis with the specified risk factor as the dependent variable and the indicator for baseline or follow-up visit as the independent variable. We ran separate regressions for women with baseline pre-diabetes, newly diagnosed diabetes, and previously diagnosed diabetes. To control for correlation among participants who were nested within local project sites, we ran a multilevel mixed model, with participant identification (ID) and state/tribal organisation ID as grouping variables using the xtmixed command in Stata. 18, 19 P-values ≤0.05 were considered significant.
Results
Demographic characteristics of the WISEWOMAN participants are listed in Table 1 . The percentages of women with pre-diabetes and diabetes, including the numbers of those newly diagnosed, are given in Figure 3 . The demographic characteristics of the women differed by diabetes status (Table 1) .
WISEWOMAN participants who returned for their one-year follow-up examination showed several statistically significant improvements in CVD risk factors ( 
Discussion
Our results showed that WISE-WOMAN participants were at high risk of diabetes-related complications at baseline and that their mean blood glucose values were increasing over time (Figure 2 heart disease risk factors among people with diabetes or pre-diabetes.
Results of our analysis are subject to several limitations. First, we do not have data on the changes that would have occurred among this population in the absence of participation in WISEWOMAN projects.
An assessment of trends in baseline risk factors (such as those presented in Figure 2 for mean blood glucose values) serves as an imperfect test of whether secular trends are driving the results. A decreasing trend in baseline risk factors across sixmonth cohorts of newly enrolled participants would suggest that other factors not related to WISE-WOMAN may be associated with improvements among participants. However, over this six-year period, baseline blood glucose values among newly enrolled participants have increased significantly ( Figure  2 ) and baseline BP and cholesterol values remained unchanged (trend was not statistically different from zero, results available upon request). Even among the general population of 40-64 year-old women, there is no evidence of decreasing blood glucose values (Figure 2) . Secondly, it is unclear whether the outcomes were a result of a single programme component or a combination. Evidence suggests that each WISEWOMAN component (i.e. screening, lifestyle intervention, referral services, and oneyear follow-up examination) has been effective in similar populations. 4, 14, 15, 20 Furthermore, in our previous work we found that some improvements in CHD risk factors among women with abnormal risk factors at baseline can be attributed to medication use, but most improvements are probably driven by a combination of other factors. These include the receipt of screening, risk factor counselling and lifestyle interventions. 21 Thirdly, the WISEWOMAN programme has a low follow-up rate (23%). WISEWOMAN participants are recruited from NBCCEDP; as a result, women who lose their eligibility for NBCCEDP because they obtain health insurance, increase their incomes, or reach 66 years of age are automatically ineligible for WISE-WOMAN. Although we observed some statistically significant differences in demographic and baseline health characteristics between participants who returned and those who did not return for their one-year follow-up examination, the differences were fairly small (except for smoking
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The Our analysis shows that WISE-WOMAN participants achieved clinically modest improvements in heart disease and stroke risk factors over a one-year period. If these small reductions could be sustained on a population-wide level, they could lead to large reductions in CHD morbidity and mortality. Moreover, a previous cost-effectiveness analysis of WISE-WOMAN has shown that this programme compares favourably with other public health interventions aimed at improving CHD risk factors, even when considering the challenges and barriers of reaching this financially vulnerable population. 22 Potential barriers to reaching the low-income, under-insured, and uninsured women served by WISE-WOMAN include provider skepticism about women's ability to change their behaviours and the women's social isolation, unsafe neighbourhoods and lack of access to healthy foods: [23] [24] [25] [26] in some locations, for example, neighbourhood stores do not stock highquality, affordable fruits and vegetables or low-fat snacks. Because the women face many structural barriers, WISEWOMAN projects are encouraged to use the socioecological model 27 to develop multifaceted interventions that address intrapersonal, organisational, community, and policy influences on health and health behaviours. For example, to strengthen family and peer support, which has been shown to improve health outcomes, [28] [29] [30] [31] [32] some WISEWOMAN projects now invite relatives and friends to participate in the interventions. WISEWOMAN staff work collaboratively with women to change their behaviours.
Organisations are also developing creative strategies using WISE-WOMAN funding. 33 In North Carolina, for example, a county health department clinic partnered with a community free clinic to extend its operating hours so that WISEWOMAN participants could attend appointments more easily. At the community level, some projects have hired community healthcare workers from participants' neighbourhoods to conduct outreach, make telephone calls to encourage attendance at medical examinations and intervention sessions, arrange transportation, help find low-cost medications, and provide other support services. Some projects provide discount passes to encourage exercise in safe environments or discount coupons to community weight-loss programmes.
As WISEWOMAN projects explore ways to serve as agents of social change, they are building alliances among disadvantaged women and their families, healthcare providers, and neighbourhoods. The WISEWOMAN programme's ability to eliminate social-group disparities in diabetes incidence and mortality probably depends on the strength of these alliances. The goal of the WISEWOMAN programme in promoting more comprehensive interventions is to empower women to use all available services, to facilitate the adoption of a healthier lifestyle. The programme also hopes to garner the social support needed for behavioural change, raise providers' expectations, build trust between patients and providers, ensure that healthcare environments address the needs of culturally diverse populations effectively, remove community barriers to healthy lifestyles, and create advocates for better healthcare coverage.
If WISEWOMAN projects can successfully implement multilevel interventions and demonstrate their effectiveness, this approach is likely to be adopted on a much broader scale. As progress is made toward this goal, the WISEWOMAN programme will begin to realise its vision of a world where any woman can access preventive health services and gain the wisdom to improve her health.
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